ClearPoint Neuro, Inc.

CLPT Healthcare Medical Devices

ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024. In the quarter to June 2026, revenue grew 18.1%, EPS fell 81.0%, free cash flow fell 173.5% and total debt rose 74.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

9.07 0.57 −5.91%
Market cap
$294.1M
P/E
0.0×
Fwd P/E
−11.6×
Dividend yield
—
F-score
4/9
Altman Z
0.44
Beneish M
−1.74
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
2 4 4 3

+8 more TTM periods

ROE
(226.52%) (149.72%) (95.64%) (103.13%)
ROA
(46.21%) (47.08%) (37.30%) (46.03%)
ROIC
(61.31%) (50.31%) (48.45%) (207.44%)
Return on Tangible Assets
(83.08%) (60.16%) (46.05%) (50.98%)
Average Days of Receivables
72.48 77.85 64.66 42.53
Free Cash Flow per Share
(1.04) (0.90) (0.86) (0.49)
Free Cash Flow
(31.29) (26.70) (24.45) (13.82)
Capital Expenditures
(1.11) (0.98) (0.52) (0.74)
Other line items
Cash ROIC
(34.62%) (25.66%) (19.87%) (16.60%)
Accounts Receivable Turnover
6.68 6.60 6.57 8.72
Accounts Payable Turnover
8.58 8.63 11.00 15.83
Inventory Turnover
2.09 2.02 1.88 1.95
Average Days of Payables
49.71 55.59 32.11 19.87
Days of Inventory on Hand
203.48 204.55 213.67 180.91
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
37.47% 37.03% 37.59% 40.75%
Selling, General and Administrative Expense of Revenue
98.56% 90.50% 89.15% 86.84%
Share Based Compensation of Revenue
20.09% 20.90% 22.13% 23.02%
Interest Coverage
(5.99) (6.84) (9.41) —
Operating CF/Net income
0.87 0.88 0.94 0.57
Depreciation/Fixed assets
1.31 1.08 0.89 0.91
Capex/Depreciation
(0.28) (0.31) (0.22) (0.38)
Revenue per Share
1.40 1.37 1.31 1.21
Operating CF per Share
(1.00) (0.87) (0.84) (0.46)
Capex per Share
(0.04) (0.03) (0.02) (0.03)
Capex to Sales
0.03 0.02 0.01 0.02

Fold the line items

Columns are period end dates